[Treatment strategy for high-grade B-cell lymphoma]

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• High-grade B-cell lymphoma (HGBL) is a recently defined entity in the WHO classification.
• HGBL encompasses subtypes with specific genetic rearrangements, including MYC and BCL2/BCL6 (double-hit), and HGBL not otherwise specified.
• Existing treatment protocols, such as R-CHOP, show suboptimal outcomes for HGBL, especially double-hit variants.

Purpose of the Study:

• To review current clinical data on High-grade B-cell lymphoma.
• To evaluate the efficacy of existing treatment strategies for HGBL.
• To propose reasonable treatment strategies for HGBL patients, considering upfront stem cell transplantation.

Main Methods:

• Review of retrospective and prospective studies on HGBL.
• Analysis of clinical data from patients with HGBL.
• Evaluation of treatment outcomes based on therapeutic regimens.

Main Results:

• Patients with HGBL, particularly double-hit HGBL, exhibit poor prognosis with standard R-CHOP therapy.
• Limited established treatment regimens and strategies exist for HGBL.
• Ongoing studies aim to identify more effective treatment protocols.

Conclusions:

• There is a critical need for optimized treatment strategies for HGBL.
• Further research is required to establish the role of interventions like upfront stem cell transplantation.
• Developing standardized treatment protocols is essential for improving outcomes in HGBL patients.